Nasvax Advances Most in Three Months on Trial of Liver Treatment

Nasvax Ltd. (NSVX) rose the most in almost three months after its parent company Biomedix Incubator Ltd. (BMDX) said Nasvax’s Phase 2a clinical trial of a treatment for fatty liver was successful.

Nasvax shares climbed as much as 8.9 percent, the biggest intraday gain since Dec. 27, to 1.63 shekels. They traded 2.3 percent higher at 1.53 shekels as of 11:24 a.m. in Tel Aviv. Biomedix increased 3.6 percent to 0.607 shekel.

To contact the reporter on this story: Ronit Goodman in Tel Aviv at

To contact the editor responsible for this story: Claudia Maedler at

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.